Highlights of ASH in Asia

Ultima Vez Modificado: 17 de enero del 2013

Share article


Dates: March 23-24, 2013
Location: Shanghai, China

Sponsoring Group: The American Society of Hematology

Web Page URL: www.hematology.org/calendar_HOAAsia

Topics Covered: Acute Myeloid Leukemia Bone Marrow Failure Chronic Lymphocytic Leukemia Disorders of Hemostasis Hematopoietic Stem Cell Transplantation Hodgkin and Non-Hodgkin Lymphoma Myelodysplastic Syndromes Myeloproliferative Neoplasms Including Chronic Myeloid Leukemia Novel Treatments for Relapsed/Refractory Chronic Immune Thrombocytopenia Plasma Cell Disorders (Myeloma) Thrombosis and Anticoagulation Thrombotic Thrombocytopenic Purpura (TTP)/Hemolytic Uremic Syndrome (HUS) and Atypical HUS

Objectives: At Highlights of ASH you will:

  • Examine advances in clinical and translational hematologic research
  • Evaluate the role of new diagnostic techniques and therapeutic approaches as applied to the care and management of people with blood diseases
  • Discuss new patient management and care strategies with leading faculty in the field

Fees: $125-275

Continuing Education: No


News
ASH: Carfilzomib Ups Survival in Relapsed Multiple Myeloma

Dec 9, 2014 - The addition of carfilzomib to lenalidomide and dexamethasone improves progression-free survival in patients with relapsed multiple myeloma, according to a study published online Dec. 6 in the New England Journal of Medicine. The findings were released to coincide with the annual meeting of the American Society of Hematology, held from Dec. 6 to 9 in San Francisco.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.


OncoLink OncoPilot

Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

Más información